Asianet NewsableAsianet Newsable

Coronavirus vaccines capped at Rs 250 at private hospitals, to be provided for free at government facilities

 Two doses to be taken in a gap of 28 days will cost Rs 500. This price will include taxes, reports said.

Coronavirus vaccines capped at Rs 250 at private hospitals, to be provided for free at government facilities-dnm
Author
New Delhi, First Published Feb 28, 2021, 9:59 AM IST

New Delhi: Coronavirus vaccines will be capped at Rs 250 per shot at private hospitals and health centres, the Health Ministry said on Saturday. Vaccines will be free in all government hospitals and centres.

Two doses to be taken in a gap of 28 days will cost Rs 500. This price will include taxes, reports said.

The decision to rope in private hospitals in the ongoing vaccination drive comes following an uptick in the number of daily infections.

Meanwhile, registration for the next round of vaccinations against Covid-19 is likely to start from Monday morning, enabling people to schedule their vaccinations on the same day.

They can register through the government's CoWIN 2.0 portal, the Aarogya Setu app, or walk into vaccination centres; states will also actively mobilise people.

Senior citizens will require a photo identity while those who will register themselves on the grounds of co-morbidities will require medical certificates. A new version of Co-Win app will be launched on March 1 with the option of self-registration.

The government on Friday had said it will let people choose their coronavirus vaccination centres when the campaign expands Monday to cover those over 60 and those over 45 with illnesses.

While, the participation of Private Sector in the inoculation drive has been scaled up with around 10,000 hospitals under Ayushman Bharat-PMJAY and 687 hospitals under CGHS to be used by states as COVID Vaccination Centres (CVCs).

But the inoculation campaign has progressed slower than expected due to a reluctance of health and front-line workers to take the home-grown COVAXIN shot that was approved without late-stage efficacy data.

Follow Us:
Download App:
  • android
  • ios